FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Remorseful Regulator Leads Reform Fight
- Lightning Round: AT&T, Verizon, Novartis and More
- Lightning Round OT: Alcoa, Weight Watchers and More
- Why Amazon Rules Retail
- Nordic American: Sinking Ship or Titan Tanker?
- Cramer: What Monday’s Housing Number Really Means
- Cramer: Buy These Banks, If...
- Time to Buy Treasurys?
- Lightning Round: Las Vegas Sands, ADC Telecom, Satyam Computer and More
- Lightning Round OT: Knight Capital, Ebix and More
Text Size 
Cramer highlighted a defensive stock on Monday's Mad Money straight from the aisles of the local drugstore that many investors have probably never even heard of: Chattem [CHTT
Loading...
()
].
Recognize the name? How about the brands? Chattem is the company behind drugstore staples like Icy Hot, Gold Bond, Selsun Blue, Pamprin, Garlique and Herpecin-L. These over-the-counter healthcare products, toiletries and dietary supplements take up huge amounts of aisle space at the drug store, which is exactly how Cramer measures this company's success. "It's as recession resistant as they come," he said.
Chattem has caught a double since Cramer last recommended it in April 2006. How does it perform with such a disparate pastiche of brands? Well, the company is a master of picking up the scraps of neglected junk brands and turning them around, Cramer said.
The business model is heavy on the ad spending because advertising is what boosts brands. Chattem also produces many of its brands in-house, manufacturing the products themselves to raise profit margins. Finally, it takes the brands it supports and extends the product lines to increase sales. Nine brand extensions are planned for this year alone. The model has worked flawlessly so far, Cramer said, and it should continue.
The real catalyst that could send Chattem even higher is an acquisition. Normally, it would be tough to value the acquisitions of Chattem's brands. But last month brought a big clue when Adams Respiratory [ARXT
Loading...
()
] – maker of Mucinex – got taken out by Reckitt Benckiser at a 37% premium. If that same sales multiple is applied to Chattem, the $75 stock could go to $84 with ease, Cramer said.
A takeover target with a watertight business model, Chattem has been quietly conquering the aisles at the drugstore one shelf at a time. Cramer thinks the upside will continue.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes